Akso Health Group (AHG) stock
AHGNasdaqServices-Business Services, NECFiscal year ends March 31
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Mar 31, 2026Last filing: 20-F on Jul 23, 2026Score 7/30
$1.36+0.12 (+9.57%)
Close on Nov 18, 2026Market cap $1.16BP/E 45.3Yield –
Akso Health r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2022 it was $421.19K, down 4.6% from the year before. The highest annual figure on record is $2.82M in fiscal 2018.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2022 | Mar 31, 2022 | $421.19K | -4.6% |
| FY2021 | Mar 31, 2021 | $441.41K | +274.3% |
| FY2020 | Mar 31, 2020 | $117.94K | – |
| FY2019 | Mar 31, 2019 | $0 | -100.0% |
| FY2018 | Mar 31, 2018 | $2.82M | +79.7% |
| FY2017 | Mar 31, 2017 | $1.57M | +75.0% |
| FY2016 | Mar 31, 2016 | $895.99K | – |
See a number that looks wrong?